4.8 Article

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

期刊

NATURE COMMUNICATIONS
卷 13, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-022-31495-x

关键词

-

资金

  1. Department of Health and Social Care
  2. Northern Ireland Government
  3. Scottish Government
  4. University of Oxford
  5. China Scholarship Council
  6. National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance [NIHR200915]
  7. UK Health Security Agency (UKHSA)
  8. Department of Health
  9. NIHR Oxford Biomedical Research Centre
  10. Huo Family Foundation
  11. Medical Research Council UK [MC_UU_12023/22]
  12. Wellcome [110110/Z/15/Z]
  13. NIHR Oxford BRC Senior Fellowship award
  14. Robertson Fellowship
  15. NIHR Oxford BRC Senior Fellowship
  16. Wellcome Trust [110110/Z/15/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

Individuals who have previously been infected with SARS-CoV-2 and receive a single dose of vaccine generate similar antibody responses to those who have not been infected and receive two doses of vaccine. Prior infection significantly enhances antibody responses, resulting in higher peak levels and/or longer half-lives after one dose of any of the three vaccines. In those with prior infection, the median time above the positivity threshold was over 1 year after the first vaccination. Single-dose vaccination targeted to those previously infected may provide at least equivalent protection to two-dose vaccination among those without previous infection.
Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out in many settings, there is a need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity. We evaluate whether a single vaccination in individuals who have already been infected with SARS-CoV-2 generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single vaccination with ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults median (50 (IQR: 37-63) years) receiving at least one vaccination, 13,404 (13.3%) had serological/PCR evidence of prior infection. Prior infection significantly boosted antibody responses, producing higher peak levels and/or longer half-lives after one dose of all three vaccines than those without prior infection receiving one or two vaccinations. In those with prior infection, the median time above the positivity threshold was >1 year after the first vaccination. Single-dose vaccination targeted to those previously infected may provide at least as good protection to two-dose vaccination among those without previous infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据